{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:54:26Z","timestamp":1778007266981,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T00:00:00Z","timestamp":1586563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Data on the use of dolutegravir for treatment of HIV-2 infection are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the effectiveness of dolutegravir in people living with HIV-2 (PLHIV-2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective chart review was performed in two clinics in Western India. PLHIV-2 initiated on dolutegravir-based regimens were included. Response to treatment in both treatment-naive (TN) and treatment-experienced (TE; substitution and not in the context of failure) was assessed by CD4 counts and HIV-2 viral load (VL) in a proportion of individuals. The primary objective was to assess immunological effectiveness (absence of a drop in absolute CD4 counts by more than 30% of baseline). Change in absolute CD4 counts was assessed by fitting a mixed-effects model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-two PLHIV-2 treated with dolutegravir were included. The immunological effectiveness rates (95% CI) were 91.9% (82.4%\u201396.5%), 92% (81.1%\u201396.8%) and 91.6% (64.6%\u201398.5%) amongst all, TE and TN individuals, respectively. Median change in absolute CD4 counts at 6, 12 and 18\u2009months were +29\u2009cells\/mm3, +101\u2009cells\/mm3 and +72\u2009cells\/mm3, respectively. The virological effectiveness rates (HIV-2 VL &amp;lt;100\u2009copies\/mL) (95% CI) for all, TE and TN individuals were 88.8% (74.6%\u201395%), 89.6% (73.6%\u201396.4%) and 85.7% (48.6%\u201397.4%), respectively. Three clinical events were documented: spinal tuberculosis, relapsed non-Hodgkin\u2019s lymphoma and herpes simplex virus retinitis. One individual reported self-limiting somnolence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dolutegravir was well tolerated and associated with immunological, virological and clinical effectiveness in both TN and TE PLHIV-2 in a large cohort from Western India. Dolutegravir-based ART is an excellent option for treatment of individuals with HIV-2 infection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa112","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T12:24:43Z","timestamp":1583497483000},"page":"1950-1954","source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness of dolutegravir-based antiretroviral treatment for HIV-2 infection: retrospective observational study from Western India"],"prefix":"10.1093","volume":"75","author":[{"given":"Sanjay","family":"Pujari","sequence":"first","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6575-2460","authenticated-orcid":false,"given":"Atul","family":"Patel","sequence":"first","affiliation":[{"name":"Infectious Diseases Clinic, Ahmedabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Gaikwad","sequence":"first","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketan","family":"Patel","sequence":"first","affiliation":[{"name":"Infectious Diseases Clinic, Ahmedabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Digamber","family":"Dabhade","sequence":"first","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Chitalikar","sequence":"first","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kedar","family":"Joshi","sequence":"first","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Bele","sequence":"first","affiliation":[{"name":"Institute of Infectious Diseases, Pune, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,11]]},"reference":[{"key":"2020061904541335100_dkaa112-B1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2013.12.001","article-title":"Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection","volume":"102","author":"Menendez-Arias","year":"2014","journal-title":"Antiviral Res"},{"key":"2020061904541335100_dkaa112-B2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4103\/0974-777X.116872","article-title":"HIV-2 infection: where are we today?","volume":"5","author":"Ingole","year":"2013","journal-title":"J Global Infect Dis"},{"key":"2020061904541335100_dkaa112-B3","first-page":"463704","article-title":"Antiretroviral therapy for HIV-2 infection: recommendations for management in low-resource settings","volume":"2011","author":"Peterson","year":"2011","journal-title":"AIDS Res Treat"},{"key":"2020061904541335100_dkaa112-B4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/1471-2334-14-461","article-title":"Antiretroviral therapy response among HIV-2 infected patients: a systematic review","volume":"14","author":"Ekouevi","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2020061904541335100_dkaa112-B5","year":"2019"},{"key":"2020061904541335100_dkaa112-B6","doi-asserted-by":"crossref","first-page":"e0222229","DOI":"10.1371\/journal.pone.0222229","article-title":"Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and meta-analysis","volume":"14","author":"Cruciani","year":"2019","journal-title":"PLoS One"},{"key":"2020061904541335100_dkaa112-B7","doi-asserted-by":"crossref","first-page":"e52562","DOI":"10.1371\/journal.pone.0052562","article-title":"Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS One"},{"key":"2020061904541335100_dkaa112-B8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/cid\/ciy245","article-title":"First-line raltegravir\/emtricitabine\/tenofovir combination in human immunodeficiency virus type 2 (HIV-2) infection: a phase 2, noncomparative trial (ANRS 159 HIV-2)","volume":"67","author":"Matheron","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020061904541335100_dkaa112-B9","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/jac\/dkz007","article-title":"Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain","volume":"74","author":"Requena","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020061904541335100_dkaa112-B10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/QAD.0b013e3282f51203","article-title":"Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients","volume":"22","author":"Damond","year":"2008","journal-title":"AIDS"},{"key":"2020061904541335100_dkaa112-B11","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciy324","article-title":"A trial of a single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for the initial treatment of human immunodeficiency virus type 2 infection in a resource-limited setting: 48-week results from Senegal, West Africa","volume":"67","author":"Ba","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020061904541335100_dkaa112-B12","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3851\/IMP2303","article-title":"The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series","volume":"17","author":"Peterson","year":"2012","journal-title":"Antivir Ther"},{"key":"2020061904541335100_dkaa112-B13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(14)70711-X","article-title":"Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial","volume":"14","author":"Grinsztejn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2020061904541335100_dkaa112-B14","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/jac\/dkx090","article-title":"Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response","volume":"72","author":"Requena","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020061904541335100_dkaa112-B15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcv.2015.01.001","article-title":"Dolutegravir for the treatment of HIV-2 infection","volume":"64","author":"Trevino","year":"2015","journal-title":"J Clin Virol"},{"key":"2020061904541335100_dkaa112-B16","first-page":"1521","article-title":"Dolutegravir in HIV-2-infected patients with resistant virus to first-line integrase inhibitors from the French named patient program","volume":"60","author":"Descamps","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020061904541335100_dkaa112-B17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000332025","article-title":"Special aspects of the treatment of HIV-2-infected patients","volume":"55","author":"Camacho","year":"2012","journal-title":"Intervirology"},{"key":"2020061904541335100_dkaa112-B18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1747-0285.2008.00647.x","article-title":"Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use","volume":"71","author":"Brower","year":"2008","journal-title":"Chem Biol Drug Des"},{"key":"2020061904541335100_dkaa112-B19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12977-015-0146-8","article-title":"In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2","volume":"12","author":"Smith","year":"2015","journal-title":"Retrovirology"},{"key":"2020061904541335100_dkaa112-B20","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/cir123","article-title":"Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: the ACHIEV2E Collaboration Study Group","volume":"52","author":"Benard","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020061904541335100_dkaa112-B21","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/jac\/dkx210","article-title":"CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study","volume":"72","author":"Wittkop","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020061904541335100_dkaa112-B22","doi-asserted-by":"crossref","first-page":"20044","DOI":"10.7448\/IAS.19.1.20044","article-title":"Immunologic response in treatment-na\u00efve HIV-2-infected patients: the IeDEA West Africa cohort","volume":"19","author":"Balestre","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2020061904541335100_dkaa112-B23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijantimicag.2019.03.016","article-title":"Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients","volume":"54","author":"Chen","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2020061904541335100_dkaa112-B24","doi-asserted-by":"crossref","first-page":"e16813","DOI":"10.1097\/MD.0000000000016813","article-title":"DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients","volume":"98","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2020061904541335100_dkaa112-B25","author":"Wyk","year":"2019"},{"key":"2020061904541335100_dkaa112-B26","doi-asserted-by":"crossref","first-page":"e0129886","DOI":"10.1371\/journal.pone.0129886","article-title":"Plasma HIV-2 RNA according to CD4 count strata among HIV-2-infected adults in the IeDEA West Africa Collaboration","volume":"10","author":"Ekouevi","year":"2015","journal-title":"PLoS One"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1950\/33404957\/dkaa112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1950\/33404957\/dkaa112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T08:55:30Z","timestamp":1592556930000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/7\/1950\/5819174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,11]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,4,11]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa112","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,4,11]]}}}